A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia

Trial Profile

A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Raxatrigine (Primary)
  • Indications Trigeminal neuralgia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Biogen
  • Most Recent Events

    • 01 Dec 2017 Planned End Date changed from 13 May 2021 to 5 May 2021.
    • 01 Dec 2017 Planned primary completion date changed from 13 May 2021 to 5 May 2021.
    • 01 Dec 2017 Planned initiation date changed from 30 Apr 2018 to 5 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top